Attached files
file | filename |
---|---|
EX-99.1 - WEIKANG BIO-TECHNOLOGY GROUP CO., INC. | v204243_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): November 29, 2010
WEIKANG
BIO-TECHNOLOGY GROUP COMPANY, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
333-1365354
|
26-2816569
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
No.
365 Chengde Street, Daowai District, Harbin
Heilongjiang
Province, The People’s Republic of China 150020
(Address
of principal executive offices) (zip code)
(86)
0451-88355530
(Registrant’s
telephone number, including area code)
Not Applicable.
(Former
name or former address, if changed since last report.)
Copies
to:
Marc J.
Ross, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32nd
Floor,
New York,
NY 10006
Tel:
(212) 930 9700
Fax:
(212) 930 9725
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01
|
Regulation
FD Disclosure.
|
On
November 29, 2010, Weikang Bio-Technology Group Co., Inc., a Nevada corporation
(the “Company”) issued a press release to announce its earnings guidance for the
fiscal year 2011. The copy of the press release is attached hereto as Exhibit
99.1.
In
accordance with General Instruction B.2 of Form 8-K, the information in Item
7.01 of this Current Report on Form 8-K, including Exhibits 99.1, shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that section,
and shall not be deemed to be incorporated by reference into any of the
Company’s filings under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the
date hereof and regardless of any general incorporation language in such
filings, except to the extent expressly set forth by specific reference in such
a filing.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
|
Exhibits.
|
99.1
|
Press
release, dated November 29, 2010, issued by Weikang Bio-Technology Group
Co., Inc.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
December 1, 2010
|
WEIKANG
BIO-TECHNOLOGY GROUP COMPANY, INC.
|
||
|
By:
|
/s/ Yin Wang | |
Yin Wang | |||
Chief
Executive Officer and Chairman of the Board
|
|||